Eluxadoline

Eluxadoline, sold under the brand names Viberzi and Truberzi is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use in the United States in 2015.The drug originated from Janssen Pharmaceutica and was developed by Actavis. In March 2017, the U.S. Food and Drug Administration issued a safety alert for eluxadoline concerning an increased risk of serious pancreatitis in patients without a gallbladder.